Background
==========

The relationship between ghrelin, a 28-amino acid peptide secreted primarily by the oxyntic cells of the stomach \[[@B1]\] and involved in body mass regulation, and *Helicobacter pylori*(*H pylori*), a bacterium that colonises the stomach, has remained controversial. The first report suggesting an association between the two was that by Nwokolo et al \[[@B2]\] who examined the effect of *H pylori*eradication on plasma ghrelin levels in 12 healthy adult male and female subjects. They reported that eradicating *H pylori*from the subjects was associated with an increase in plasma ghrelin levels. At about the same time, Gockel et al \[[@B3]\] reported that *H pylori*had no effect on plasma ghrelin levels in a study of 39 age- and BMI-matched *H pylori*positive and negative women. Subsequently a number of other papers, including animal studies, have explored this relationship \[[@B4]-[@B7]\]. A number of review articles have also appeared exploring this relationship \[[@B8],[@B9]\]; but none of these has been conducted systematically.

Considering the putative role of ghrelin in body mass regulation, understanding this association could help in maximizing its benefits, and also provide further insight into the physiology of appetite and body mass regulation. The objective of this review is to examine available evidence to determine whether or not a relationship exists between ghrelin and *H pylori*infection; and where one exist, to investigate the direction of the association. Specifically, this review sets out to answer three questions: 1) Is *H pylori*infection associated with circulating ghrelin levels? 2) what is the effect of eradicating *H pylori*infection on circulating ghrelin levels?; and 3) what is the effect of *H pylori*infection on ghrelin producing cells in the stomach?

Methods
=======

Literature search strategy and data extraction
----------------------------------------------

A comprehensive search of the scientific literature (Medline (OVID), OvidMedline (R) 1950 - October Week 2 plus In-process & Non-indexed citations, Embase (1980 to 2010 week 41), and ISI Web of Knowledge) was conducted using the search terms \"ghrelin AND *helicobacter pylori*\". The search was repeated several times. The last search was conducted on October 29, 2010. Further searches were conducted using Google scholar; while the bibliography of original and review articles were searched for studies with ghrelin and *helicobacter pylori*in their titles. Duplicate searches were first removed; thereafter, the abstracts of retrieved articles were reviewed for relevance prior to accessing the full paper. Only English-language primary studies on humans were included provided that the authors assessed at least one of the following: 1) compared circulating ghrelin concentration in *H pylori*positive and negative subjects; 2) compared the effect of eradicating *H pylori*on circulating ghrelin levels; or 3) compared gastric ghrelin in *H pylori*positive and negative subjects or changes in gastric ghrelin after *H pylori*eradication. Letters in response to published articles, commentaries, and editorials were excluded. Conference abstracts that had not been published as full papers were included where the full abstracts could be retrieved, provided that such conference abstract contained enough information for either the qualitative or the quantitative synthesis. However, where a conference abstract has been published as a full paper, the full paper was retrieved and the conference proceeding excluded.

Efforts were made to contact authors of conference abstracts whose full paper publications could not be traced to inquire if the paper had been published as a full paper and if not, to get further details about the study. Efforts were also made to contact authors of papers where some relevant information was missing to request for the missing information or for further clarifications. We contacted 18 authors \[[@B2],[@B6],[@B10]-[@B25]\]; but only nine authors \[[@B2],[@B14],[@B18],[@B21]-[@B26]\] responded and provided the needed information. We were unable to contact one author \[[@B27]\].

We also attempted to group the papers reviewed by study teams in other to assess the spread of the papers reviewed. In deciding whether different papers were published by the same research groups, similarity in authorship was examined. Where at least one author contributed to different publications, those publications were deemed to have emanated from the same research group.

Outcomes evaluated
------------------

Outcomes evaluated included: differences in circulating ghrelin levels between *H pylori*positive and negative subjects; changes in circulating ghrelin concentration after *H pylori*eradication; differences in ghrelin mRNA between *H pylori*positive and negative subjects; changes in ghrelin mRNA after *H pylori*eradication; differences in ghrelin immunoreactive cells between *H pylori*positive and negative subjects; changes in ghrelin immunoreactive cells after cure; correlation between ghrelin immunoreactive cells with severity of *H pylori*infection; correlation between gastric and plasma ghrelin; correlation between ghrelin mRNA and plasma ghrelin; and correlation between cells and plasma ghrelin.

Data synthesis
--------------

The data extracted were classified into three classes: 1) data comparing circulating ghrelin concentration in *H pylori*positive and negative subjects; 2) data comparing the circulating ghrelin concentration before and after *H pylori*eradication; and 3) data assessing any of the gastric ghrelin parameters. Each of these classes was supposed to answer a specific question (Table [1](#T1){ref-type="table"}). The variables were re-coded in forms that would make analysis easier (Table [2](#T2){ref-type="table"}). Table [3](#T3){ref-type="table"} lists the papers excluded from the review and the reasons for their exclusion.

###### 

Research questions explored by the review

  Research question                                                                 Explanatory data
  --------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Is *H pylori*infection associated with circulating ghrelin levels?                Data comparing circulating ghrelin concentration in *H pylori*positive and negative subjects
  What is the effect of eradicating *H pylori*on circulating ghrelin levels?        Data comparing the circulating ghrelin concentration before and after *H pylori*eradication
  What is the effect of *H pylori*infection on ghrelin expression in the stomach?   Data assessing any of the gastric ghrelin parameters

###### 

Dictionary of variables used in the review

  Variable                                                                               Coding scheme
  -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  **Study Team**                                                                         A, B, C etc
  **Design**                                                                             Cohort, Cross-sectional, Case control, Experimental
  **Healthy**                                                                            Healthy only, Sick only, Both
  **Region**                                                                             Asia, Africa, Europe, North America, South America
  **Gender**                                                                             Male only, Female only, Both
  **Age**                                                                                Children only, Adults only, Both
  **Number of methods used to assess *H pylori***                                        One method; two or more methods
  **Type of ghrelin assay used**                                                         Commercial RIA, in-house RIA, Commercial ELISA, Commercial EIA
  **Sample storage**                                                                     -70°C and below; above -70°C
  **Sample type**                                                                        Serum; Plasma
  **Weight**                                                                             Normal, Low, Various, High
  **Difference in circulating ghrelin concentration between *H pylori*+ & - subjects**   Lower, no difference, higher
  **Changes in circulating ghrelin after cure**                                          Increased, decreased, no change
  **Duration of follow-up**                                                              4 weeks & below; Above 4 weeks
  **Sample size**                                                                        Two categorizations were done: 1) 50 & below, 51-200, 201 and above; 2)Above 20, Below 20

Statistical analysis
--------------------

Simple proportions were used to determine the frequency of occurrence of each categorical variable considered; and association between different variables assessed using Fisher\'s exact chi^2^test. Continuous variables like sample size and duration of follow-up was initially summarized using medians and inter-quartile ranges and later categorized as shown in Table [2](#T2){ref-type="table"}. Multiple logistic regression analysis was used to assess confounding. The descriptive analysis was conducted using Stata version 8 (StataCorp LP, College Station, Texas, USA).

Meta-analysis
-------------

We conducted meta-analyses of summary statistics from individual studies that compared circulating ghrelin levels between *H pylori*positive and *H pylori*negative subjects; and for studies that compared circulating ghrelin levels before and after eradication of *H pylori*. For each study, the mean circulating ghrelin concentrations and standard deviations (sd) for the different comparison groups were used to generate standardized mean differences (SMDs) and 95% confidence intervals (95% CI) since different studies used different units to measure ghrelin concentration, and some studies measured plasma ghrelin while others measured serum ghrelin. For studies that reported standard errors of mean, standard deviation was derived using the formula provided in the Cochrane Handbook of clinical reviews: SD = SEM × √N (<http://www3.interscience.wiley.com/homepages/106568753/handbook.pdf>). Studies that reported only medians and 95% CI or interquartile ranges (IQR) \[[@B2],[@B6]\] were not included in the meta-analysis. Table [4](#T4){ref-type="table"} lists studies excluded from the meta-analysis and the reasons for their exclusion.

Study specific estimates were combined using the inverse variance method with weighted average for continuous outcomes in a random effects model. Heterogeneity was assessed using the chi-squared method and the I^2^method described by Higgins et al \[[@B28],[@B29]\]. For studies that reported different sub-groups separately \[[@B30]-[@B32]\] those sub-groups were included as separate papers in the meta-analysis. Chuang et al, \[[@B30]\] reported ghrelin levels for males and females separately. While the data for males did not increase the heterogeneity of the studies, inclusion of the data for females introduced significant heterogeneity to the analysis. All the papers that resulted in significant heterogeneity of the studies in the meta-analysis were removed from the meta-analysis. A separate meta-analysis conducted for this sub-group of excluded studies revealed a significant heterogeneity (P=0.0001; I^2^= 86%) and the effect size was very small and not significant (SMD -0.13 \[-0.33, 0.06\], Test for overall effect: Z = 1.36 (P = 0.17)). These papers were therefore completely excluded from the meta-analysis and described in a narrative. Sensitivity analysis was conducted to assess the contribution of each study to the pooled estimate by excluding individual studies one at a time and recalculating the pooled SMD estimates for the remaining studies. Funnel plots were used initially to assess publication bias and later confirmed using Begg\'s and Egger\'s tests. The meta-analyses were conducted using Review Manager Version 5 (RevMan 5; <http://www.cc-ims.net/revman/download>), while the Begg\'s and Egger\'s tests were conducted using Stata version 8 after downloading the installation files for the tests from the internet.

Results
=======

Search results
--------------

The literature search yielded 1361 papers (404 from databases and 957 from Google Scholar) plus one unpublished paper. After removing duplicate articles, reviews, commentaries and letters (written in response to published articles), 166 papers (including one conference abstract and one unpublished paper) were left. These were further screened using titles and abstract to assess for eligibility, resulting in the exclusion of 106 articles (Figure [1](#F1){ref-type="fig"}). The full texts of the remaining 60 articles (excluding the conference abstract) were retrieved. Twenty-two papers were subsequently dropped from the review (Table [3](#T3){ref-type="table"}), and another 11 from the meta-analysis (Table [4](#T4){ref-type="table"}).

![PRISMA flow chart showing information flow in the selection of papers for the review](1471-230X-11-7-1){#F1}

###### 

Papers excluded from the review

                                          Reason for exclusion
  --------------------------------------- ------------------------------------------------------------------------------------------------------
  Suzuki et al, 2006 \[[@B54]\]           Did not report ghrelin levels in *H pylori*positive &*H pylori*negative patients
  Nunes et al, 2006 \[[@B27]\]            Not sufficient information in abstract and authors could not be contacted for further clarifications
  Campana et al, 2007 \[[@B56]\]          All subjects were *H pylori*negative
  Isomoto et al, 2005 \[[@B52]\]          Compared only *H pylori*strains
  Checchi et al, 2007 \[[@B10]\]          Did not compare serum ghrelin levels in *H pylori*positive &*H pylori*negative subjects
  Wu et al, 2005\[[@B57]\]                Did not assess ghrelin
  Shinomiya et al, 2005\[[@B58]\]         Did not compare the difference in ghrelin between *H pylori*positive &*H pylori*negative subjects
  Suzuki et al, 2005\[[@B59]\]            Did not assess ghrelin
  Sundbom et al, 2007\[[@B60]\]           Did not assess *H pylori*
  Huang et al, 2007\[[@B61]\]             Did not assess *H pylori*
  Nishizawa et al, 2006\[[@B62]\]         Did not assess *H pylori*
  Ando et al, 2006\[[@B63]\]              Did not assess ghrelin
  Kempa et al, 2007\[[@B64]\]             All subjects were *H pylori*negative
  Ates et al, 2008\[[@B65]\]              Did not assess *H pylori*
  Wang et al, 2006\[[@B66]\]              Did not assess ghrelin
  Doki et al, 2006\[[@B67]\]              Did not assess *H pylori*
  Gao et al, 2008\[[@B68]\]               Excluded people with *H pylori*
  Cherian et al, 2009\[[@B69]\]           Did not assess ghrelin
  Kebapcilar et al, 2009\[[@B70]\]        Did not assess ghrelin
  Dutta et al, 2009\[[@B71]\]             Did not assess ghrelin
  Gen et al, 2010\[[@B72]\]               Did not assess ghrelin
  Taniaka-Shintani et al, 2005\[[@B1]\]   Examined only ghrelin immunoreactive cells

###### 

Papers excluded from the meta-analysis

  -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nwokolo et al, 2003\[[@B2]\]                 Reported median values & 95% CI; also measured integrated ghrelin levels rather than the discrete measurement that other authors used. The authors stated that the median values were used because the sample size was small and the data were skewed
  Mendez-Sanchez et al, 2007 \[[@B49]\]        Studied ghrelin immuno-reactive cells, did not provide data on plasma ghrelin levels
  Salles et al, 2006\[[@B19]\]                 Ghrelin values not provided. Only P-values
  Gao et al, 2009\[[@B15]\]                    Ghrelin values not provided
  Choe et al, 2007\[[@B6]\]                    Median & IQR provided. Further clarifications not provided by the authors
  Czesnikiewicz-Guzik et al, 2005\[[@B12]\]    Insufficient information for meta-analysis
  Czesnikiewicz-Guzik et al, 2007 \[[@B13]\]   Insufficient information for meta-analysis
  Masaoka et al \[[@B51]\]                     This was a case study with only one subject
  Stec-Michalska et al, 2009\[[@B24]\]         Measured only gastric ghrelin
  Liew et al, 2006\[[@B47]\]                   Assessed only gastric ghrelin
  Konturek et al, 2006\[[@B17]\]               The numbers of H pylori positive and negative participants were not provided and the authors did not respond to requests for further information.
  -------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Is H pylori infection associated with circulating ghrelin levels?
-----------------------------------------------------------------

Table [5](#T5){ref-type="table"} is an evidence table of studies that compared circulating ghrelin levels in *H pylori*positive and *H pylori*negative individuals. Twenty-six studies compared circulating ghrelin levels between *H pylori*positive and negative subjects. The analysis of one of the studies \[[@B30]\] was stratified by gender, yielding different results; this study was therefore entered into the evidence table as two separate papers with each gender representing one paper, bringing the total number of papers reviewed to 27. One paper \[[@B22]\] was not included in the evidence table because the grouping of the subjects studied did not permit a straight forward comparison of the *H pylori*positive and *H pylori*negative subjects. The paper was therefore reviewed in a separate narrative. Table [6](#T6){ref-type="table"} summarises the characteristics of the studies included in the evidence table. Most of the studies (77%) investigated both males and females, 85% studied only adults and 52% studied sick subjects mainly subjects with gastrointestinal symptoms (64.7%) and Cancer (17.65%). Thirteen (48.2%) of the studies \[[@B15],[@B21],[@B30],[@B33]-[@B41]\] were conducted in Asia; 11 (40.7%) \[[@B3],[@B11],[@B12],[@B17],[@B19],[@B26],[@B31],[@B32],[@B42]-[@B44]\] in Europe and three (11.1%) \[[@B14],[@B18],[@B45]\] in North America. Twenty-two percent of the studies reviewed were contributed by one research group alone, while Japan contributed 30% of the papers. More than two-thirds of the studies used radioimmunoassay to measure serum or plasma ghrelin, 55.6% assessed *H pylori*using two or more methods, and in all the studies except one, samples were collected after overnight fast. All comparisons were based on the pre-meal ghrelin levels. In most of the studies (70.4%), the samples were stored at a temperature of -70°C or below until analysed; ghrelin was measure in plasma samples in 63% of the studies, while the participants were of normal weight in 58% of the studies. The sample sizes for the different studies ranged from 13 to 538 (median: 89; IQR: 62, 180).

###### 

Evidence table of studies that compared circulating ghrelin levels in Hp+ and Hp- individuals

  Reference & Country                                  Study Team   Design             Healthy   Gender   Age        Method of *H pylori*assessment                   Ghrelin assay kit   Overnight fast   Sample storage   Sample type   Weight          Sample size   Ghrelin levels in Hp+ vs Hp-
  ---------------------------------------------------- ------------ ------------------ --------- -------- ---------- ------------------------------------------------ ------------------- ---------------- ---------------- ------------- --------------- ------------- ------------------------------
  Kawashima et al, 2009; Japan \[[@B38]\]              A            Cohort             Both      Both     Adults     Serology                                         Commercial EIA      Yes              -80              Plasma        Normal          220           Lower
  Plonka et al, 2006; Poland \[[@B32]\]                B            Cohort             Healthy   Both     Both       Modified UBT plus ELISA                          Commercial RIA      Yes              -80              Serum                         538           Lower
  Isomoto et al, 2005; Japan\[[@B36]\]                 C            Cohort             Sick      Both     Adults     RUT, histology (Giemsa stain)                    In-house RIA        Yes              -80              Plasma        Normal          81            Lower
  Roper et al, 2008; USA \[[@B18]\]                    D            Cross-sectional    Healthy   Men      Adults     serology, histology & RUT or positive culture    Commercial EIA      Yes              -20              Serum         Normal          256           No Difference
  Pacifico et al, 2008; Italy \[[@B26]\]               E            Cohort             Both      Both     Children   Culture of gastric specimen or histology + RUT   Commercial RIA      Yes              -70              Serum         Normal          85            No Difference
  Gokcel, 2003; Turkey \[[@B3]\]                       F            Case control       Sick      Women    Adults     Not stated                                       Commercial EIA      Yes              Not stated       Plasma        Normal          39            No Difference
  Plonka et al, 2006; Poland \[[@B43]\]                B            Case control       Healthy   Both     Children   Serology and UBT                                 Commercial RIA      Yes              -80              Serum         Various         287           Lower
  Shiotani et al, 2005; Japan \[[@B21]\]               G            Case control       Healthy   Both     Adults     Detection of HP IgG ab in the urine              Commercial ELISA    Yes              Not stated       Serum         Various         132           Lower
  Osawa et al, 2005; Japan \[[@B40]\]                  C            Case control       Sick      Men      Adults     Culture & histology                              In-house RIA        Yes              -30              Plasma        Normal          160           Lower
  Chuang et al\*, 2009; Taiwan \[[@B30]\]              H            Cross-sectional    Sick      Men      Adults     Not described                                    Commercial RIA      Yes              -72              Plasma        low to normal   145           Lower
  Chuang et al\*, 2009; Taiwan \[[@B30]\]              H            Cross-sectional    Sick      Women    Adults     Not described                                    Commercial RIA      Yes              -72              Plasma        low to normal   196           No Difference
  Alonso et al, 2007; Spain\[[@B42]\]                  P            Cross-sectional    Sick      Both     Adults     UBT, histology (Giemsa stain)                    Commercial RIA      Yes              -80              Plasma        Normal          15            Lower
  Salles et al, 2006; France\[[@B19]\]                 I            Cross-sectional    Sick      Both     Adults     UBT, serology, culture, histology & PCR          Commercial RIA      Yes              -80              Plasma        low to normal   62            Lower
  Jun et al, 2007; Korea \[[@B37]\]                    J            Cross-sectional    Sick      Both     Adults     RUT, histology (Giemsa stain)                    Commercial RIA      Yes              -70              Plasma        Normal          63            No Difference
  D\'Onghia et al, 2007; Italy \[[@B31]\]              K            Case control       Both      Both     Adults     ELISA                                            RIA                 Yes              -20              Serum         Various         79            Lower
  Gao et al, 2009; China \[[@B15]\]                    L            Case control       Healthy   Both     Adults     Serology & UBT.                                  Commercial RIA      Yes              -80              Plasma        Normal          100           Lower
  Isomoto et al, 2005; Japan\[[@B35]\]                 C            Cross-sectional    Sick      Both     Adults     Anti-IgG antibody, 13C-UBT, or RUT               In-house RIA        Yes              -80              Plasma        Normal          89            Lower
  Isomoto et al, 2005; Japan\[[@B41]\]                 C            Cross- sectional   Sick      Both     Adults     Serology, UBT or RUT                             In-house RIA        Yes              -80              Plasma        Normal          249           Lower
  An et al, 2007; Korea\[[@B33]\]                      Q            Cohort             Sick      Both     Adults     Not stated                                       Commercial ELISA    Yes              -70              Plasma        Normal          41            No difference
  Nishi et al, 2005; Japan \[[@B39]\]                  C            Cross-sectional    Both      Both     Adults     Serology & UBT                                   In-house RIA        Yes              -80              Plasma        Normal          74            Lower
  Czesnikiewicz-Guzik et al, 2005; Poland \[[@B12]\]   B            Cross-sectional    Healthy   Women    Adults     UBT                                              Not stated          Not stated       Not stated       Serum         Not Stated      100           Lower
  Konturek et al, 2006; Poland \[[@B17]\]              B            Cross-sectional    Healthy   Both     Both       UBT & serology                                   Human RIA           Yes              -80              Serum         Not Stated      180           Lower
  Cindoruk et al, 2007; Turkey \[[@B11]\]              M            Cohort             Sick      Both     Adults     Either histology or UBT                          RIA                 Yes              -80              Plasma        Normal          50            No Difference
  Isomoto et al, 2004; Japan \[[@B34]\]                C            Cohort             Sick      Both     Adults     Serology                                         Commercial RIA      Yes              -80              Plasma        Normal          68            Lower
  de Martel, 2007; USA \[[@B14]\]                      N            Case control       Sick      Both     Adults     In-house ELISA                                   Commercial ELISA    Yes              -80              Serum         Various         110           No Difference
  Shak et al, 2008, USA\[[@B45]\]                      R            Cohort             Healthy   Both     Adults     Serology                                         Commercial EIA      Yes              -20              Plasma        Obese           24            No difference
  Uzzan et al, 2007\[[@B44]\]                          S            Cohort             Healthy   Both     Adults     Histology                                        Commercial RIA      Yes              Not stated       Serum         Obese           13            No difference

\* These are from the same paper reporting the same study but were separated because the analysis was stratified by gender and the results for males and females were completely different; hence the decision to separate them.

###### 

Summary of the characteristics of the studies reviewed in Table 5

  Characteristic                                  n    n %
  ---------------------------- ------------------ ---- -------
  Study Design                 Case control       7    25.93
                               Cohort             9    33.33
                               Cross-sectional    11   40.74
                                                       
  Gender studied               Both               21   77.78
                               Men                3    11.11
                               Women              3    11.11
                                                       
  Region                       Asia               13   48.15
                               Europe             11   40.74
                               North America      3    11.11
                                                       
  Health status                Both               4    14.81
                               Healthy            9    33.33
                               Sick               14   51.85
                                                       
  Age Group                    Adults             23   85.19
                               Both               2    7.41
                               Children           2    7.41
                                                       
  Type of Sickness             Cancer             3    17.65
                               GI symptoms        11   64.71
                               Others†            3    17.64
                                                       
  HP assessment methods used   Not Described      5    18.52
                               One                7    25.93
                               Two or more        15   55.56
                                                       
  Assay Type                   Commercial EIA     4    14.81
                               Commercial ELISA   3    11.11
                               Commercial RIA     14   51.85
                               In-house RIA       5    18.52
                               Not stated         1    3.7
                                                       
  Sample Size                  50 and below       6    22.22
                               51-200             16   59.26
                               201 and above      5    18.52
                                                       
  Sample Storage               -70C and above     19   70.37
                               Below -70C         4    14.81
                               Not Described      4    14.81
                                                       
  Sample type                  Plasma             17   62.96
                               Serum              10   37.04
                                                       
  BMI of participants          Normal             15   57.69
                               Not Stated         2    7.69
                               Obese              2    7.69
                               Various            4    15.38
                               low to normal      3    11.54

†Others include Crohn\'s disease (1), diabetes mellitus (1) and multiple conditions (1)

Overall, 17 studies (63%) reported that circulating ghrelin concentrations were lower in *H pylori*positive subjects. Ten studies from Asia (76.9%) and seven from Europe (63.6%) found that circulating ghrelin levels in *H pylori*positive subjects were lower compared to *H pylori*negative subjects. The rest of the studies, including the three from the USA did not find any difference between *H pylori*positive and negative subjects. There was a weak association between the region of the world where the study was conducted and the finding of a lower circulating ghrelin level in *H pylori*positive subjects compared to *H pylori*negative subjects (Fisher\'s exact test = 0.07). This completely disappeared after controlling for gender, age, health status, type of sample used, storage conditions, BMI, and the sample size.

Zub-Pokrowiecka et al \[[@B22]\] investigated ghrelin changes in the plasma and gastric mucosa among participants with various gastric diseases. Their subjects were divided into four groups - Group 1 had gastric cancer and concomitant *H pylori*infection; group 2 had antral gastritis, duodenal ulcer and *H pylori*infection; group 3 had atrophic gastritis of the fundus and corpus of the stomach but no *H pylori*infection; while group 4 had no gastric lesions and no *H pylori*infection. These researchers reported that the fasting plasma ghrelin concentrations varied among the different groups as follows (in descending order): group 2, group 4, group 1 and group 3.

### Meta-analysis

Twenty-one of the 26 studies reviewed in this section qualified for inclusion in the meta-analysis. Of these 21 studies, three studies provided ghrelin values for the different categories of subjects studied. Chuang et al \[[@B30]\] presented their results by gender; D\'Onghia et al \[[@B31]\] presented their results according to whether the subjects were healthy controls or had colo-rectal cancer; and Plonka et al \[[@B32]\] presented their results for adults and children separately. Because each of these features could affect the circulating ghrelin concentration, the different categories were entered into the meta-analysis as separate papers bringing the total number of papers included to 24 with a total of 2244 participants. Table [4](#T4){ref-type="table"} lists studies excluded from the meta-analysis. Four papers were subsequently removed from the final analysis because they added significant heterogeneity to the analysis (Figure [2](#F2){ref-type="fig"}). The analysis showed that circulating ghrelin concentration was significantly lower in *H pylori*positive participants than in *H pylori*negative participants (Effect estimate (95%CI) = -0.48 \[-0.60, -0.36\]). Figure [2](#F2){ref-type="fig"} is a forest plot of SMDs of circulating ghrelin concentration between *H pylori*positive and *H pylori*negative subjects. There was no significant heterogeneity among the studies (Heterogeneity: Chi² = 24.21, df = 19 (P = 0.19); I² = 22%). Examination of the funnel plot (Figure [3](#F3){ref-type="fig"}) suggests some publication bias but the Egger and Begg\'s tests indicated no publication bias (Begg\'s test: z = 1.20 (continuity corrected), P = 0.23 (continuity corrected); Egger\'s bias coefficient = -59.99, P = 0.116). A sensitivity analysis indicated that all the studies included in the meta-analysis contributed approximately equally to the pooled estimate (Table [7](#T7){ref-type="table"}). Three of the studies dropped from the meta-analysis did not find any difference in the circulating ghrelin levels between *H pylori*positive and *H pylori*negative subjects \[[@B14],[@B26],[@B30]\]. However, Plonka et al \[[@B32]\] found a significantly lower circulating ghrelin levels among a group of *H pylori*positive Polish shepherds compared to their *H pylori*negative controls. Adding these four papers (excluded because of heterogeneity) only slightly increased the effect estimate (-0.42 \[-0.57, -0.27\]) but still showed that *H pylori*infection was associated with a lower circulating ghrelin concentration.

![**Forest plot of SMDs of circulating ghrelin concentration between H pylori positive and H pylori negative subjects (the top forest plot labelled \'actual\' represents the analysis on which the inference was made**. The lower forest plot labelled \'removed\' were studies excluded from the meta-analysis but displayed here to demonstrate their characteristics for readers that might be interested. The values at the bottom of the forest plot represents the overall effect size for both the \'actual\' and the \'removed\'](1471-230X-11-7-2){#F2}

![Funnel plot of SMDs of circulating ghrelin concentration between H pylori positive and H pylori negative subjects](1471-230X-11-7-3){#F3}

###### 

Sensitivity analysis of studies included in the meta-analysis

  Studies excluded                SMD (95%CI)              Test for overall effect
  ------------------------------- ------------------------ -------------------------
  Alonso et al, 2007              -0.47 \[-0.59, -0.35\]   Z = 7.80 (P \< 0.00001)
  An et al, 2007                  -0.49 \[-0.61, -0.37\]   Z = 7.88 (P \< 0.00001)
  Chuang et al_male, 2009         -0.48 \[-0.61, -0.35\]   Z = 7.39 (P \< 0.00001)
  Cindoruk et al, 2007            -0.49 \[-0.61, -0.38\]   Z = 8.48 (P \< 0.00001)
  D\'Onghia et al_case, 2007      -0.47 \[-0.60, -0.35\]   Z = 7.64 (P \< 0.00001)
  D\'Onghia et al_control, 2007   -0.49 \[-0.61, -0.37\]   Z = 7.95 (P \< 0.00001)
  Gokcel et al, 2003              -0.49 \[-0.61, -0.36\]   Z = 7.84 (P \< 0.00001)
  Isomoto et al, 2004             -0.46 \[-0.57, -0.35\]   Z = 7.96 (P \< 0.00001)
  Isomoto et al, 2005a            -0.47 \[-0.60, -0.35\]   Z = 7.47 (P \< 0.00001)
  Isomoto et al, 2005b            -0.47 \[-0.59, -0.34\]   Z = 7.43 (P \< 0.00001)
  Isomoto et al, 2005c            -0.48 \[-0.61, -0.35\]   Z = 7.14 (P \< 0.00001)
  Jun et al, 2007                 -0.49 \[-0.61, -0.36\]   Z = 7.72 (P \< 0.00001)
  Kawashima et al, 2009           -0.48 \[-0.61, -0.35\]   Z = 7.32 (P \< 0.00001)
  Nishi et al, 2005               -0.49 \[-0.59, -0.39\]   Z = 9.72 (P \< 0.00001)
  Osawa et al, 2005               -0.46 \[-0.58, -0.34\]   Z = 7.45 (P \< 0.00001)
  Plonka et al_ch1 2006           -0.46 \[-0.58, -0.34\]   Z = 7.65 (P \< 0.00001)
  Roper et al, 2008               -0.51 \[-0.63, -0.39\]   Z = 8.37 (P \< 0.00001)
  Shak et al, 2008                -0.48 \[-0.60, -0.36\]   Z = 7.79 (P \< 0.00001)
  Shiotani et al, 2005            -0.46 \[-0.59, -0.34\]   Z = 7.33 (P \< 0.00001)
  Uzzan et al, 2007               -0.47 \[-0.59, -0.35\]   Z = 7.76 (P \< 0.00001)

What is the effect of eradicating H pylori on circulating ghrelin levels?
-------------------------------------------------------------------------

Table [8](#T8){ref-type="table"} presents an evidence table of the studies that reported the effect of eradicating *H pylori*on circulating ghrelin levels. Thirteen papers were reviewed 12 of which were cohort studies and one RCT. Five of the 13 studies were conducted in Japan; 3 in Korea (both in Asia) and four in Europe. The only study from Africa was an unpublished paper by our team. Table [9](#T9){ref-type="table"} is a summary of the characteristics of the studies in Table [8](#T8){ref-type="table"}.

###### 

Evidence table of studies that examined changes in circulating ghrelin levels following *H pylori*eradication

  Reference & Country                                  Study Team   Design   Healthy   Gender   Age category   HP assess                                                          Ghrelin assay Kit   Sample storage   Sample type   Weight       Sample size   Circulating Ghrelin levels after cure   Follow-up (wks)
  ---------------------------------------------------- ------------ -------- --------- -------- -------------- ------------------------------------------------------------------ ------------------- ---------------- ------------- ------------ ------------- --------------------------------------- -----------------
  Nwokolo et al, 2003; UK \[[@B2]\]                    A            Cohort   Healthy   Both     Adults         Serology and UBT                                                   Commercial RIA      -20              Plasma        Various      10            Increased                               6
  Jang et al, 2008; Korea \[[@B16]\]                   B            Cohort   Sick      Both     Adults         RUT plus histology & confirmed by UBT                              Commercial RIA      -70              Plasma        Normal       16            Increased                               Not stated
  Osawa et al, 2006; Japan \[[@B46]\]                  C            Cohort   Healthy   Men      Adults         Bacterial culture & histology                                      In-house RIA        Not stated       Plasma        Normal       134           Decreased                               12
  Czesnikiewicz-Guzik et al, 2007; Poland \[[@B13]\]   D            Cohort   Sick      Women    Adults         UBT; culture of saliva & supragingival dental plaques + serology   Commercial RIA      -80              Plasma        Not stated   49            Increased                               4
  Lee et al, 2010; Korea \[[@B23]\]                    B            RCT      Healthy   Both     Adults         RUT, histology (Giemsa stain)                                      ELISA               -70              Plasma        Normal       9             No difference                           5
  Choe et al, 2007, Korea \[[@B6]\]                    E            Cohort   Sick      Both     Adults         histology & PCR                                                    Commercial ELISA    -70              Plasma        Normal       8             No difference                           4
  Pacifico et al, 2008; Italy \[[@B26]\]               F            Cohort   Both      Both     Children       Culture of gastric specimen or histology + RUT                     RIA                 -70              Serum         Normal       22            Decreased                               52
  Nweneka, et al, unpublished; Gambia                  G            Cohort   Sick      Both     Children       UBT                                                                Commercial RIA      -70              Serum         Low          3             Decreased                               4
  Isomoto et al, 2005; Japan \[[@B36]\]                C            Cohort   Sick      Both     Adults         RUT, histology (Giemsa stain)                                      In-house RIA        -80              Plasma        Normal       43            No difference                           4
  Isomoto et al, 2005; Japan\[[@B35]\]                 C            Cohort   Sick      Both     Adults         RUT, histology (Giemsa stain)                                      In-house RIA        -80              Plasma        Normal       10            No difference                           4
  Kawashima et al, 2009; Japan \[[@B38]\]              H            Cohort   Both      Both     Adults         Serology                                                           Commercial EIA      -80              Plasma        Normal       49            Increased                               23
  Cindoruk et al, 2007; Turkey \[[@B11]\]              I            Cohort   Sick      Both     Adults         Either histology or UBT                                            RIA                 -80              Plasma        Normal       23            No difference                           12
  Isomoto et al, 2004; Japan \[[@B34]\]                C            Cohort   Sick      Both     Adults         Serology                                                           Commercial RIA      -80              Plasma        Normal       9             No difference                           4

###### 

Summary of the characteristics of the studies reviewed in Table 8

  Characteristic                 n                 \%   
  ------------------------------ ----------------- ---- -------
  Study Design                   Cohort            12   92.31
                                 RCT               1    7.69
                                                        
  Gender studied                 Both              11   84.62
                                 Men               1    7.69
                                 Women             1    7.69
                                                        
  Region                         Africa            1    7.69
                                 Asia              8    61.54
                                 Europe            4    30.77
                                                        
  Health status                  Both              2    15.38
                                 Healthy           3    23.08
                                 Sick              8    61.54
                                                        
  Age Group                      Adults            11   84.62
                                 Children          2    15.38
                                                        
  Type of Sickness               GI Symptoms       9    90
                                 PEM               1    10
                                                        
  HP assessment methods used     One               3    23.08
                                 Two or more       10   76.92
                                                        
  Assay Type                     ELISA             2    15.38
                                 Commercial RIA    8    61.54
                                 In-house RIA      3    23.08
                                                        
  Sample Size                    Above 20          6    46.15
                                 Below 20          7    53.85
                                                        
  Sample Storage                 -70°C and below   11   84.62
                                 Above -70°C       1    7.69
                                 Not described     1    7.69
                                                        
  Sample type                    Plasma            11   84.62
                                 Serum             2    15.38
                                                        
  BMI of participants            Normal            10   76.92
                                 Others            3    23.07
                                                        
  Duration of follow-up          4 weeks & below   6    46.15
                                 Above 4 weeks     6    46.15
                                 Not recorded      1    7.69
                                                        
  Change in ghrelin after cure   Decreased         3    23.08
                                 Increased         3    23.08
                                 No difference     7    53.85

In 11 studies, the subjects fasted overnight, and for 3 hours (between 6am and 9am) in one study, before being bled. Osawa et al \[[@B46]\] did not indicate whether their subjects were fasted or not. The sample sizes varied from 3 to 134; median value was 16 (IQR: 9, 43). The duration of follow-up varied from 4 weeks to 52 weeks (median follow-up time: 4.5 weeks; IQR: 4 weeks, 12 weeks). Jang et al \[[@B16]\] were not clear on the duration of follow-up of their subjects.

In seven studies (53.9%) there was no significant difference in circulating ghrelin levels pre- and post *H pylori*eradication. Three studies (23.1%) reported an increase above the pre-eradication level while 3 (23.1%) reported a decrease below the pre-eradication levels. Cross tabulation of the following variables with change in circulating ghrelin levels following cure of *H pylori*infection did not show any association: the age of the participants, the type of sample used, duration of follow-up, sample size, weight of participants, temperature at which the blood samples were stored, the assay kit used to measure circulating ghrelin, the number of methods used to assess *H pylori*, gender, country and the region where the study was conducted. Although not statistically significant, the circulating ghrelin concentration decreased following *H pylori*eradication in the two studies that measured ghrelin using serum samples (Fisher\'s exact test 0.08). Similarly, the two studies conducted on children found a decrease in circulating ghrelin levels after *H pylori*cure. However, these two studies on children also utilised serum samples; while all the 11 studies conducted in adults used plasma samples. From this descriptive analysis, there is not sufficient data to make a conclusive statement on the effect of *H pylori*eradication on circulating ghrelin levels.

### Meta-analysis

Nine (out of the 13 studies reviewed in this section) were included in a meta-analysis with a total population of 592. The excluded studies are listed in Table [4](#T4){ref-type="table"}. The analysis showed that eradicating *H pylori*does not have any significant effect on circulating ghrelin levels (Effect estimate (95% CI) = -0.08 \[-0.33, 0.16\]; Test for overall effect: Z = 0.67 (P = 0.5)). Figure [4](#F4){ref-type="fig"} is a forest plot of SMDs of circulating ghrelin concentration pre- and post-eradication of *H pylori*. The funnel plot indicated publication bias (Figure [5](#F5){ref-type="fig"}).

![Forest plot of SMDs of circulating ghrelin concentration pre- and post- eradication of h pylori](1471-230X-11-7-4){#F4}

![Funnel plot of SMDs of circulating ghrelin concentration pre- and post- eradication of H pylori](1471-230X-11-7-5){#F5}

What is the effect of H pylori infection on ghrelin expression in the stomach?
------------------------------------------------------------------------------

Thirteen studies examined the effects of *H pylori*infection on gastric ghrelin. This includes six cohort studies \[[@B6],[@B36],[@B44],[@B46]-[@B48]\], 2 case-control studies \[[@B40],[@B49]\], four cross-sectional studies \[[@B18],[@B19],[@B24],[@B37]\] and one randomised controlled trial \[[@B23]\]. The participants included sick subjects (7), well subjects (3) and both well and sick subjects (2). Eight studies were conducted in Asia, two in France, one each in Poland, Brazil and USA. Ten studies recruited both males and females, and three recruited males only. All the sick participants had gastrointestinal symptoms. Different methods were used to assess *H pylori*infection either alone or in combination: histology (11 studies), culture (3), rapid urease assay (5), serology (3), urea breath test (2) and PCR (4). Ten of the 13 studies were conducted on normal weight subjects, two on obese subjects and one on subjects of different body weights. Due to the different gastric ghrelin parameters assessed, a meta-analysis was not possible.

Five studies assessed gastric ghrelin contents: one found it to be lower in *H pylori*positive subjects \[[@B36]\], three \[[@B6],[@B18],[@B44]\] found no significant difference between *H pylori*positive and negative participants, and one \[[@B24]\] found increased levels in *H pylori*positive participants. Isomoto et al \[[@B36]\] compared gastric ghrelin peptide contents in the endoscopic biopsies from the corpus of 56 *H pylori*positive and 25 *H pylori*negative subjects using radio-immunoassay. They reported significantly lower gastric ghrelin content in the *H pylori*positive subjects than the *H pylori*negative subjects. Roper et al \[[@B18]\] studied 216 adult males of normal BMI presenting for routine endoscopy consisting of 120 *H pylori*positive and 96 *H pylori*negative subjects. Although they did not find any significant difference in the gastric ghrelin levels between *H pylori*positive and *H pylori*negative subjects, they reported a very wide variation in the concentration of ghrelin in the gastric juice (from \<80 to 776,000 pg/ml) with the *H pylori*positive subjects having higher gastric juice ghrelin levels than the *H pylori*negative subjects. Choe et al \[[@B6]\] did not find any significant difference in the gastric ghrelin levels between *H pylori*positive and *H pylori*negative subjects using biopsied tissues.

Four studies examined the expression of ghrelin mRNA in gastric mucosa \[[@B19],[@B36],[@B37],[@B40]\]. Three studies found ghrelin mRNA expression to be lower in *H pylori*positive subjects than in *H pylori*negative subjects, while Jun et al \[[@B37]\] found no difference. Five studies assessed the quantity of ghrelin immunoreactive cells in the gastric mucosa \[[@B36],[@B40],[@B47]-[@B49]\]; all of which found that *H pylori*positive subjects had fewer ghrelin-producing cells than in uninfected subjects. However, in the study by Isomoto et al \[[@B36]\], this difference did not achieve statistical significance.

Five studies compared the various gastric ghrelin parameters before and after *H pylori*eradication \[[@B6],[@B23],[@B36],[@B46],[@B48]\]. Choe et al \[[@B6]\] did not find any significant difference in the ghrelin concentration in the antrum, corpus and fundus pre- and post- *H pylori*eradication. Lee et al \[[@B23]\] reported a randomized controlled trial on *H pylori*positive volunteers without peptic ulcer or any other gastrointestinal symptoms in which the treatment group received triple *H pylori*eradication regimen while the control group did not receive any treatment. These authors reported a significant increase in gastric ghrelin mRNA expression following eradication compared to the control group. Osawa et al \[[@B46]\] also reported an increase in ghrelin mRNA expression following *H pylori*cure. Although Isomoto et al \[[@B36]\] found a tendency towards increase in ghrelin mRNA expression following cure of *H pylori*, this increase was not significant. Tatsuguchi et al \[[@B48]\], on the other hand, found an increase in ghrelin immunoreactive cells following *H pylori*eradication in 50 patients with either peptic ulcer disease or gastritis, while in 11 patients who did not respond to eradication therapy, there was no difference in the number of ghrelin immunoreactive cells pre-and post-eradication therapy.

Three studies \[[@B36],[@B47],[@B49]\] found a negative correlation between ghrelin producing cells in the gastrum and the severity of *H pylori*infection. Gastric ghrelin content and gastric ghrelin mRNA expression were both positively correlated with plasma ghrelin concentration \[[@B36],[@B46]\].

Discussion
==========

The potential role of ghrelin in body mass regulation makes understanding its interactions with *Helicobacter pylori*, a highly prevalent gastrointestinal infection, important. To address this issue, we asked three questions: how does *H pylori*infection affect circulating ghrelin levels; how does eradicating *H pylori*affect circulating ghrelin; and how does *H pylori*infection affect gastric ghrelin and ghrelin producing cells.

The results of our analysis has conclusively shown that circulating ghrelin levels are significantly higher in *H pylori*negative people than in those infected with *H pylori*(P = 0.00001). Our results also suggest that eradicating *H pylori*does not have any significant effect on circulating ghrelin. Although there was no significant heterogeneity between the group of studies that compared circulating ghrelin concentrations before and after *H pylori*eradication, this result should be interpreted with the following caveats in mind: 1) three of the studies \[[@B34]-[@B36]\] included in the meta-analysis came from the same research group; and together accounted for 29% of the effect size; 2) the paper by Osawa et al \[[@B46]\] which reported higher ghrelin levels before *H pylori*eradication compared to the levels after eradication on its own contributed 26.2% of the effect; and 3) the sample sizes of most of the other studies were relatively small. Interestingly, all the smaller studies, except one, found higher circulating ghrelin levels post-eradication. Even among the subjects studied by Osawa et al \[[@B46]\], plasma ghrelin increased in 50 patients and decreased in 84 patients, although the overall effect was a decrease post-eradication. They were however, able to show that pre-eradication elevation of ghrelin was associated with a fall in ghrelin post-eradication. In our unpublished data, we also found that elevated ghrelin concentration pre-eradication was associated with a fall post-eradication. These two observations suggest that in addition to other factors, the pre-eradication ghrelin level determines the direction of response of ghrelin post-eradication.

The heterogeneity of the studies examining the effect of *H pylori*on gastric ghrelin expression as well as the small number of studies that examined different aspects of this relationship did not allow a meta-analysis to be performed. However, the descriptive data suggests that available evidence is still discrepant; although the weight of evidence seems to favour lower ghrelin mRNA and ghrelin immunoreactive cells in association with *H pylori*infection \[[@B19],[@B36],[@B40],[@B47]-[@B49]\]. The ultimate effect of *H pylori*on gastric ghrelin appears to be dependent on the duration of infection and the extent of *H pylori*-induced damage to the gastric mucosa. At least three studies found a negative correlation between number of ghrelin producing cells and the severity of *H pylori*infection \[[@B36],[@B47],[@B49]\].

The close anatomical proximity between the site of *H pylori*infection and the site of ghrelin production might result in the loss of ghrelin producing cells as part of the *H pylori*associated gastritis, causing reduced ghrelin production. However, such effect will not be restricted to *H pylori*infection and could occur in any other condition associated with gastritis. For example, Checchi et al \[[@B10]\] studied 233 patients with autoimmune gastritis (indicated by elevated parietal cell antibody (PCA)) and 211 control subjects, and found that mean serum ghrelin levels in PCA positive patients were significantly lower than in PCA negative patients, similar to the results found in *H pylori*infection by some studies. This decrease remained significant even after excluding patients with *H pylori*infection, suggesting that the *H pylori*infection was not necessarily responsible for the reduction in serum ghrelin. Again, the region of the stomach biopsied could also affect the results. Jang et al \[[@B16]\] reported that after ulcer healing and *H pylori*eradication, there was a significant increase in the levels of ghrelin mRNA. But while corpus ghrelin mRNA increased after cure and *H pylori*eradication, anthral ghrelin mRNA decreased, suggesting a differential response by the ghrelin producing cells in the different regions of the stomach. In healthy *H pylori*infected subjects however, Lee et al \[[@B23]\] found a significant increase in fundic ghrelin mRNA after eradication of *H pylori*(P = 0.0002) but no change in the anthral ghrelin mRNA (P = 0.5), suggesting a more complex relationship between gastric ghrelin production and *H pylori*infection. Teasing out this relationship will require more rigorous investigation.

If *H pylori*infection is associated with a lower circulating ghrelin, it is biologically plausible that its eradication will be associated with an increase in circulating ghrelin. But if *H pylori*reduces circulating ghrelin by destroying ghrelin producing cells, then the effect of eradicating it on circulating ghrelin would depend on the duration of infection, the amount of damage to ghrelin-producing cells, and the time it takes for these cells to regenerate. Indeed several studies have found a negative correlation between the number of ghrelin producing cells and the severity of gastritis \[[@B36],[@B47],[@B49]\]. And in one study, there was no change in ghrelin levels post-eradication after 4 weeks of follow-up, but the level progressively increased with follow-up, achieving, in some subjects, significant increase after 6 months of follow-up \[[@B36]\]. In contrast, mice infected with *H pylori*for 6-8 months had higher ghrelin levels compared to time-matched controls, which normalised two months post-eradication \[[@B50]\]. However, Masaoka et al \[[@B51]\] did not find any change in circulating ghrelin levels 2 years after successful eradication of *H pylori*in an adult man.

The discrepancy in the response to *H pylori*eradication could also be related to the strain of *H pylori*. Isomoto et al \[[@B52]\] found that strain diversity in *H pylori*was associated with plasma and gastric ghrelin levels in humans. Patients with type I strain (which express the virulence factors cytotoxin-associated gene product (CagA) and Vacuolating cytotoxin A (VacA)) have lower circulating ghrelin levels than those with the less virulent type II strain which does not express the virulence factors. This finding also argues for a possible racial difference in the association between circulating ghrelin levels and *H pylori*infection: in regions where type I strain is dominant, one would expect to see reduced circulating ghrelin levels. While such speculation is attractive, it might not be entirely correct \[[@B53]\]. In this review, the effect of region and country of study on the relationship between *H pylori*and ghrelin was very weak, and appears to be confounded by several other factors.

The underlying clinical condition of the subject might also be affecting the results. Suzuki et al \[[@B54]\] studied plasma ghrelin in patients with peptic ulcer disease. They found that plasma ghrelin levels were significantly higher in patients with duodenal ulcer as well as those with gastric ulcer compared to those with chronic gastritis. Among the subjects that were *H pylori*positive, plasma ghrelin was significantly higher in patients with duodenal or gastric ulcer than in those with non-ulcer chronic gastritis. After treatment for the ulcer (with healing), no significant change was found in the plasma ghrelin levels (i.e. pre-and post eradication levels were similar). Most of the studies reviewed here recruited subjects with varying degrees and types of gastrointestinal pathology. If each of these gastrointestinal diseases affects ghrelin production differently as suggested by Suzuki et al \[[@B54]\], then the discrepancies noted in this review are to be expected. Compensation from other sources of ghrelin production might also explain the various inconsistencies highlighted in this review. For example, Suzuki et al \[[@B55]\] infected Mongolian gerbils with *H pylori*and assessed the plasma and gastric ghrelin levels at 17 and 23 weeks after the infection. They found a significant decrease in gastric ghrelin in the *H pylori*positive gerbils compared to the controls, but also found a significant increase in plasma ghrelin levels in the *H pylori*positive group. This same group also found increased plasma ghrelin and decreased gastric ghrelin levels in IL-1R1 knockout mice \[[@B4]\] suggesting that other sources of ghrelin might have contributed to the increased plasma ghrelin.

Limitations and implications for research and practice
------------------------------------------------------

The major limitation of this review is the use of only English language papers, which raises the possibility of some publication bias. Another limitation in conducting this review is that all except one of the papers were observational studies, most of which did not primarily set out to assess the relationship between ghrelin and H pylori; but assessed both parameters in relation to other objectives. Well designed randomised clinical trials are needed to verify the conclusions made by this review. Also, many of the studies included participants with diverse disease conditions whose impacts on ghrelin secretion have not been investigated before. The best approach to solve the riddle of the relationship between ghrelin and helicobacter pylori might be to study otherwise healthy participants with asymptomatic *H pylori*infection.

Conclusions
===========

From available evidence, circulating ghrelin concentration is lower in people infected with *H pylori*compared to those not infected with the bacterium. However, a more complex relationship exists between circulating ghrelin levels and eradication of *H pylori*. This relationship may be modulated by the strain of infecting *H pylori*, the duration of follow-up, the extent of *H pylori*-induced gastritis and other underlying pathology. More studies are needed to further elucidate the impact of *H pylori*eradication on circulating ghrelin concentration.
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